Novavax Files 8-K on Financials

Ticker: NVAX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1000694

Novavax Inc 8-K Filing Summary
FieldDetail
CompanyNovavax Inc (NVAX)
Form Type8-K
Filed DateJan 13, 2025
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

TL;DR

Novavax dropped its 8-K on Jan 13th - check the exhibits for the real numbers.

AI Summary

On January 13, 2025, Novavax, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, providing an update on the company's performance. Specific financial figures and operational details are expected to be found within the attached exhibits.

Why It Matters

This filing provides investors with crucial, up-to-date information on Novavax's financial health and operational performance, which can influence investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful analysis.

Key Players & Entities

  • Novavax, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Gaithersburg, Maryland (location) — Principal Executive Offices

FAQ

What specific financial results are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific figures are within the attached documents.

When was the earliest event reported in this filing?

The earliest event reported is dated January 13, 2025.

What is Novavax, Inc.'s principal executive office address?

Novavax, Inc.'s principal executive offices are located at 700 Quince Orchard Road, Gaithersburg, Maryland 20878.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the SIC code for Novavax, Inc.?

The Standard Industrial Classification (SIC) code for Novavax, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 1,196 words · 5 min read · ~4 pages · Grade level 12.3 · Accepted 2025-01-13 07:50:30

Key Financial Figures

  • $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 13, 2025, Novavax, Inc. (the "Company") plans to provide an update for investors in which it reaffirmed its guidance for full year 2024. The Company is in the process of finalizing its financial results for the year ended December 31, 2024, and the foregoing preliminary financial data is based on available information to date. This financial data for the year ended December 31, 2024 is preliminary and may change. This preliminary financial data has been prepared by, and is the responsibility of, the Company's management. Ernst & Young LLP, the Company's independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial data, nor have any other independent accountants. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto. The Company's actual results for this period may differ from the foregoing preliminary financial data and such changes could be material. In addition, this preliminary financial data should not be viewed as a substitute for full financial that will be material to investors will be provided in these financial statements, and, accordingly, investors should not place undue reliance on the limited preliminary information being provided herein. This Current Report on Form 8-K includes forward-looking statements including statements regarding the Company's current expectations, financial results and anticipated results of operations, including full year 2024 financial guidance; expected combined annual research and development and selling, general and administrative expenses for 2025 and 2026. Generally, forward-looking statements can be identified through the use of words or phrases such as "could,"

01

Item 7.01. Regulation FD Disclosure. On January 13, 2025, the Company plans to provide an update for investors at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, presenting information relating to certain strategic and business updates (the "Investor Presentation"), which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. A copy of the Investor Presentation will also be accessible on the Company's website at www.novavax.com under "Latest Investor Presentation." Cautionary Note Regarding Forward-Looking cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Investor Presentation regarding these forward-looking statements. The information in Item 2.02 and Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing. In addition, the contents of the Company's website are not incorporated by reference into this Current Report on Form 8-K and you should not consider information provided on the Company's website to be part of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Investor Presentation of Novavax, Inc. 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: January 13, 2025 By: /s/ Mark Casey Name: Mark Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.